View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 7, 2016

Proclara begins Phase Ib trial of NPT088 to treat Alzheimer’s disease

US-based biotechnology company Proclara Biosciences has begun its Phase Ib clinical trial of NPT088 to treat Alzheimer’s disease.

US-based biotechnology company Proclara Biosciences has begun its Phase Ib clinical trial of NPT088 to treat Alzheimer’s disease.

NPT088 is an intravenously administered fusion protein based on the company’s proprietary general amyloid interaction motif (GAIM).

GAIM is used to target the common amyloid protein conformation, disrupt and inhibit the formation of misfolded protein assemblies of Aβ, tau and α-synuclein, as well as prevent the transmission of toxic element through cells.

Previously conducted in vitro preclinical studies have demonstrated the efficacy of NPT088 to target and selectively fuse with Aβ and tau aggregates and subsequently lowering its level in a mouse model of Alzheimer’s disease.

"We believe that our unique approach to targeting misfolded proteins holds great potential to transform the lives of patients suffering from devastating neurodegenerative diseases."

The Phase Ib trial has been designed as a randomised, double-blind, placebo-controlled study intended to test the safety and tolerability of multiple doses of NPT088.

The trial also intends to determine the pharmacokinetics, immunogenicity and pharmacodynamic profile of NPT088 measured by Aβ and tau PET imaging.

Proclara chief scientific officer Richard Fisher said: “It is well-established that Alzheimer’s and other neurodegenerative diseases progress from the buildup of multiple misfolded proteins, a key reason why these diseases have proven so challenging to treat.

“The initiation of the NPT088 Phase Ib trial is supported by a substantial preclinical development programme and the recent successful completion of a Phase Ia study in healthy volunteers.

“We believe that our unique approach to targeting misfolded proteins holds great potential to transform the lives of patients suffering from devastating neurodegenerative diseases, who currently have no effective, disease-modifying treatment options.”

The completion of the trial is expected to support the company’s future Phase II/III development programmes for Alzheimer’s disease and Parkinson’s disease.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena